High affinity SIRP-alpha reagents and methods of using
US11208481B2 · kind B2 · utility
4Cited by
2References
28Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 5, 2018 |
| Grant date | Dec 28, 2021 |
| Priority date | — |
| Expiry date | Aug 27, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/5005
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
High affinity SIRP-α reagent are provided, which (i) comprise at least one amino acid change relative to the wild-type protein; and (ii) have an increased affinity for CD47 relative to the wild-type protein. Compositions and methods are provided for modulating phagocytosis in a mammal by administering a therapeutic dose of a pharmaceutical composition comprising a high affinity SIRPα reagent, which blocks the physiological binding interaction between SIRPα and its ligand CD47.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.